📄 medicine

Serum thymic stromal lymphopoietin levels according to asthma and pregnancy status

This prospective study demonstrates that circulating serum TSLP levels are significantly elevated in women with asthma regardless of pregnancy status, yet these levels do not correlate with asthma severity, clinical control, or pregnancy alone.

Original authors: Barbara Beatriz Garcia Raskovisch Bartholo, Thiago Prudente Bartholo, Alessandra Lourenço Caputo Magalhães, Rogerio Rufino, Luís Cristóvão Porto, Jeane Souza Nogueira, Camila Oliveira Silva Meira, Den

Published 2026-06-26

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Barbara Beatriz Garcia Raskovisch Bartholo, Thiago Prudente Bartholo, Alessandra Lourenço Caputo Magalhães, Rogerio Rufino, Luís Cristóvão Porto, Jeane Souza Nogueira, Camila Oliveira Silva Meira, Denise Leite Maia Monteiro, Cláudia Henrique da Costa

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The Big Picture: What Are They Looking For?

Imagine your body is a house. Asthma is like having a very sensitive smoke alarm system that sometimes goes off when there isn't even a fire, causing the sprinklers (inflammation) to flood the airways.

Scientists have found a specific "alarm signal" molecule called TSLP (Thymic Stromal Lymphopoietin). Think of TSLP as the siren that starts the whole fire alarm process. When the skin or lungs sense trouble (like pollen or dust), they sound the TSLP siren, which tells the immune system to rush in and fight.

This study wanted to answer two main questions:

Does the "siren" (TSLP) sound louder in women who have asthma compared to those who don't?
Does being pregnant change how loud that siren sounds?

The Experiment: Four Groups of Women

The researchers gathered 126 women and split them into four distinct teams to compare their "siren" levels in their blood:

Team A: Pregnant women with asthma.
Team B: Pregnant women without asthma (healthy).
Team C: Non-pregnant women with asthma.
Team D: Non-pregnant women without asthma (healthy).

They took a blood sample from each woman (mostly during the second trimester for the pregnant group) and measured exactly how much TSLP was floating around.

The Results: What Did the Data Say?

1. The "Asthma" Factor: The Siren is Louder
The most important finding was that women with asthma had much higher levels of TSLP than women without asthma.

The Analogy: It's like comparing a house with a broken, constantly beeping smoke alarm (Asthma) to a house with a quiet, working alarm (No Asthma). The "beeping" (TSLP) was significantly louder in the asthma group, regardless of whether the woman was pregnant or not.
The Takeaway: Having asthma seems to keep the body's inflammatory "siren" turned up high.

2. The "Pregnancy" Factor: No Change in Volume
Surprisingly, being pregnant did not make the siren louder on its own.

The Analogy: Imagine pregnancy is like moving into a bigger house. You might expect the sound to change because the space is different. However, the study found that a healthy pregnant woman's "siren" sounded just as quiet as a healthy non-pregnant woman's. Pregnancy alone didn't crank up the volume.
The Takeaway: Pregnancy itself doesn't seem to trigger this specific inflammatory alarm system in the blood.

3. The "Severity" Factor: Loudness Doesn't Equal Danger
The researchers also checked if a louder siren meant the asthma was "worse" or harder to control.

The Analogy: They expected that a house with a really broken alarm (severe asthma) would be screaming the loudest. But they found that the volume of the siren didn't match how bad the asthma symptoms were. Some women with very mild asthma had high TSLP, and some with severe asthma had lower levels.
The Takeaway: The amount of TSLP in the blood tells us there is inflammation happening, but it cannot be used as a ruler to measure how severe the asthma is or how well it is currently controlled.

Why This Matters (According to the Paper)

The study concludes that TSLP is a marker of the activity of asthma inflammation, not a marker of how "bad" the disease feels or how pregnant a woman is.

Think of TSLP as a smoke detector.

If the detector is beeping (high TSLP), you know there is smoke (inflammation) somewhere in the system.
However, the beeping doesn't tell you if the fire is a small candle or a raging inferno (severity), nor does it tell you if the house is currently being renovated (pregnancy).

Summary of Limitations

The authors are honest about what they didn't find out:

They only took a "snapshot" in time (one blood test), so they don't know if the levels change day-to-day or week-to-week.
They didn't look at specific sub-types of asthma (like whether the inflammation was caused by eosinophils, a specific type of white blood cell), which might have explained why some people had high TSLP and others didn't.

In short: Women with asthma have higher levels of this specific "alarm molecule" in their blood than women without asthma. Pregnancy doesn't change this level, and the level doesn't predict how severe the asthma is.

Technical Summary: Serum Thymic Stromal Lymphopoietin Levels According to Asthma and Pregnancy Status

Problem Statement
Asthma during pregnancy is a significant clinical concern, as poorly controlled disease is associated with adverse maternal and perinatal outcomes. While the inflammatory mechanisms driving asthma are partially understood, the specific role of systemic biomarkers in pregnant women with asthma remains unclear. Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine known to initiate type 2 (T2) airway inflammation and has been detected at the maternal–fetal interface, potentially influencing immune tolerance. However, circulating TSLP levels in pregnant women with asthma have not been well characterized, nor is the relationship between systemic TSLP concentrations and asthma clinical characteristics (severity and control) during pregnancy established.

Methodology
This prospective observational study employed a cross-sectional biomarker assessment to compare serum TSLP concentrations across four distinct groups of women:

Pregnant women with asthma ( $n=34$ ).
Healthy pregnant women without asthma ( $n=16$ ).
Non-pregnant women with asthma ( $n=37$ ).
Healthy non-pregnant controls ( $n=39$ ).

Participants were recruited from obstetric–pulmonary and respiratory outpatient clinics at the State University of Rio de Janeiro, Brazil. Pregnant participants were assessed at a single time point during the second trimester (gestational age $\le$ 34 weeks). Strict exclusion criteria were applied to minimize confounding factors, including smoking history ( $\ge$ 10 pack-years), chronic lung diseases, autoimmune conditions, and recent malignancies.

Serum TSLP was quantified using a commercial solid-phase sandwich ELISA. Asthma control and severity were classified according to the Global Initiative for Asthma (GINA) 2025 recommendations. Given the non-normal distribution of TSLP data, statistical analysis utilized non-parametric methods: the Kruskal–Wallis test for overall group comparisons, followed by Dunn's post-hoc test for pairwise comparisons. Mann–Whitney tests were used for exploratory comparisons between pregnancy status and asthma status.

Key Contributions and Results
The study provides novel data on systemic TSLP levels in the context of both asthma and pregnancy. The primary findings are as follows:

Asthma Status Drives TSLP Elevation: Serum TSLP concentrations were significantly higher in women with asthma compared to women without asthma, regardless of pregnancy status. The combined asthma group showed a median TSLP of 58.4 pg/mL versus 18.4 pg/mL in the non-asthma group ( $p=0.001$ ).
Pregnancy Status Alone Does Not Increase TSLP: There was no statistically significant association between pregnancy status and increased circulating TSLP levels. While pregnant women with asthma had the highest median levels (63.3 pg/mL), this was attributed to their asthma status rather than pregnancy itself, as healthy pregnant women (15.9 pg/mL) did not differ significantly from healthy non-pregnant controls (18.8 pg/mL).
Lack of Correlation with Clinical Metrics: Within the asthma cohort, serum TSLP levels were not associated with asthma severity (GINA classification), asthma control status, age, or body weight.
Demographic and Clinical Disparities: The study noted that non-pregnant women with asthma had significantly lower lung function (FEV $_1$ and FVC) compared to pregnant women with asthma, yet the pregnant group exhibited poorer asthma control. Despite these clinical differences, TSLP levels remained independent of these variables.

Significance and Claims
The authors claim that these findings suggest circulating TSLP reflects asthma-related inflammatory activity rather than serving as a direct marker for clinical disease severity, asthma control, or pregnancy status alone.

The study posits that while TSLP is expressed locally at the maternal–fetal interface and may play a role in immune tolerance, these local processes do not necessarily translate into detectable differences in systemic serum concentrations. Consequently, systemic TSLP appears to function as an upstream epithelial alarmin indicative of the underlying inflammatory drive in asthma, but it does not correlate with the clinical phenotype or severity as defined by current treatment guidelines (GINA).

The paper concludes modestly, acknowledging limitations such as the cross-sectional design, modest sample size, and lack of detailed inflammatory phenotyping (e.g., eosinophil counts). It asserts that while TSLP is a relevant biomarker for asthma-related inflammation, its utility as a standalone predictor for clinical outcomes in pregnant women with asthma is limited without further longitudinal and phenotypic investigation.